Structure-activity relationships of mitochondria-targeted tetrapeptide pharmacological compounds

Area of Science:

• Mitochondrial biology and biophysics
• Medicinal chemistry and drug design
• Molecular pharmacology

Background:

• Mitochondrial dysfunction is implicated in numerous heritable and age-related diseases.
• Tetrapeptides with cationic and aromatic residues, like SS-31 (elamipretide), are promising therapeutics for mitochondrial disorders.

Purpose of the Study:

• To perform a quantitative structure-activity analysis of novel tetrapeptide analogs compared to SS-31.
• To investigate the structural basis and membrane interaction mechanisms of these mitochondria-targeted peptides.
• To evaluate the cellular efficacy of these analogs in disease-relevant models.

Main Methods:

• Quantitative structure-activity relationship (QSAR) analysis of four tetrapeptide analogs.
• Nuclear Magnetic Resonance (NMR) spectroscopy and molecular dynamics simulations for structural modeling.
• Cell-based assays to assess membrane permeability, mitochondrial targeting, and pharmacological activity in stress models.

Main Results:

• Structural models revealed distinct membrane-bound conformations, with most analogs forming reverse turns, unlike SS-31.
• All peptides interacted with cardiolipin-containing membranes, but with varying binding affinities and effects on membrane surface charge.
• Peptide analogs effectively permeated cells and targeted mitochondria, demonstrating pharmacological activity in cell stress models, with SPN10 showing superior efficacy.

Conclusions:

• Side chain composition and sequence register significantly influence the membrane interactions and biological activity of mitochondria-targeted tetrapeptides.
• Modulation of membrane electrostatics is a key mechanism of action for this peptide class.
• These findings provide a framework for the rational design of more potent, next-generation mitochondria-targeted therapeutics.